Mantle Cell Lymphoma
VIDEO: Can mantle cell lymphoma be cured? Expert explores next steps
In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of oncology at Mayo Clinic, discusses recent advancements in the treatment and study of mantle cell lymphoma.
VIDEO: BTK inhibitors may reduce need for intensive induction therapy in mantle cell lymphoma
In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of oncology at Mayo Clinic, discusses recent advancements in the treatment and study of mantle cell lymphoma.
VIDEO: CAR T-cell therapy shows promise in hard-to-treat mantle cell lymphoma
In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of oncology at Mayo Clinic, discusses recent advancements in the treatment and study of mantle cell lymphoma.
VIDEO: Immunotherapies, BTK inhibitors transforming mantle cell lymphoma field
In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of oncology at Mayo Clinic, discusses recent advancements in the treatment and study of mantle cell lymphoma.
VIDEO: Advances improve accuracy of mantle cell lymphoma diagnosis
In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of oncology at Mayo Clinic, discusses recent advancements in the treatment and study of mantle cell lymphoma.
FDA approves therapies for colorectal cancer, mantle cell lymphoma
The FDA approved two oncology regimens on Jan. 16.
Consolidative HSCT may not be necessary for some patients with mantle cell lymphoma
SAN DIEGO — Autologous hematopoietic stem cell transplantation did not benefit adults with mantle cell lymphoma in first complete remission after induction, according to randomized phase 3 data presented at ASH Annual Meeting and Exposition.
Findings highlight ‘critical importance’ of infectious complications after CAR-T
Infections are the primary cause of nonrelapse mortality among individuals who undergo chimeric antigen receptor T-cell therapy, according to study results.
Calquence delays disease progression as first-line treatment for mantle cell lymphoma
The addition of acalabrutinib to standard-of-care chemoimmunotherapy significantly extended PFS compared with standard therapy alone in a randomized study, according to press release the agent’s manufacturer.
VIDEO: Combination of BTK inhibitor with venetoclax shows promise in mantle cell lymphoma
In this video, Stephen M. Ansell, MD, PhD, discusses primary analysis results from the phase 3 Sympatico study.